ArticleTranslational stroke research2025
Plasma Metabolites of Kynurenine Pathway and Risk of Stroke in the General Population: A Nested Case-control Study.
Article in Translational stroke research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Plasma Tryptophan Hydroxylase 1 Activity-related Metabolic Markers and Stroke Risk: A Nested Case-control Study.Translational stroke research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Kynurenine pathway has been linked to several cardiovascular diseases, but their specific associations with stroke risk remain elusive. This study aimed to explore the associations between kynurenine pathway metabolites and the subsequent risk of stroke. A case-control study nested in a community-based cohort (n = 16,113) was performed between 2013 and 2018. A total of 412 incident stroke cases and 412 controls matched by age and sex were included. Plasma levels of kynurenine pathway metabolites, including tryptophan, kynurenine, kynurenic acid (KA), 3-hydroxykynurenine (3-HK), 3-hydroxy anthranilic acid (3-HAA), anthranilic acid (AA), and xanthurenic acid (XA), were measured by ultrahigh performance liquid chromatography-tandem mass spectrometry. Conditional logistic regression analyses were used to calculate odds ratios (ORs) and their 95% confidence intervals (CIs) between these biomarkers and stroke risk. After adjustment for body mass index, current smoking, marital status, estimated glomerular filtration rate, and physical activity, the corresponding OR for the highest versus lowest quintile of XA was 0.56 (95% CI: 0.36-0.89, P trend = 0.018) for total stroke risk and 0.48 (95% CI:0.28-0.81, P trend = 0.015) for ischemic stroke risk, respectively. No significant association was observed between plasma tryptophan, kynurenine, KA, 3-HK, 3-HAA, or AA and stroke risk. Our novel findings indicate an inverse association of plasma XA with the risk of total stroke and ischemic stroke in the general population. These findings highlight the potential of plasma XA as a valuable biomarker for assessing stroke risk and developing targeted prevention strategies.
Indexed as
Identifiers
41364188What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.